Table 5.

Select chemo-immunotherapy trials for chemotherapy Naïve NSCLC patients with EGFR activating mutations or ALK rearrangements.

Regimen	Patient population	Study design	NCT number	Primary outcome	Estimated completion date
Atezolizumab + Carboplatin + Pemetrexed + Bevacizumab vs. Carboplatin + Pemetrexed + Bevacizumab	Non-smokers (<100 cigarettes in a life time), EGFR activating mutation, or ALK or ROS1 rearrangement positive	Randomized phase II	NCT03786692	PFS	January 2024
Nivolumab + Carboplatin + Pemetrexed vs. Nivolumab + Ipilimumab	EGFR activating mutation or ALK rearrangement positive	Randomized phase II	NCT03256136	ORR	October 31, 2024
Pembrolizumab + Platinum + Pemetrexed vs. Platinum + Pemetrexed (KEYNOTE-789)	EGFR activating mutation positive	Randomized phase III	NCT03515837	PFS and OS	June 26, 2023
Nivolumab + Platinum + Pemetrexed vs. Nivolumab + Ipilimumab vs. Platinum + Pemetrexed (CheckMate722)	EGFR activating mutation positive	Randomized phase III	NCT02864251	PFS	December 31, 2023

Platinum includes either carboplatin or cisplatin. PD-L1, programmed death ligand 1; NCT, national clinical trials; ORR, objective response rate; PFS, progression free survival; OS, overall survival.